Allo-RevCAR01-T vs CD123 targeted CAR-NK cells

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Acute Myeloid Leukemia

Shared mechanism: CD123 · full Acute Myeloid Leukemia pipeline

Allo-RevCAR01-T

Developed by AvenCell Europe GmbH

Phase 1 in Acute Myeloid LeukemiaCAR-T
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: May 2027 · NCT05949125 (registry estimate)

No aligned efficacy figure on record for this race.

CD123 targeted CAR-NK cells

Developed by Chongqing Precision Biotech Co., Ltd

Phase 1/2 in Acute Myeloid Leukemiacell therapy (CAR-NK)
Weak signal

NCT06006403 · Phase 1/2 · completed

This was a non-randomized, open-label study with no comparator and only five participants. Its primary outcomes included safety and objective response rate, but results are not posted, so whether the primary outcomes were met cannot be determined.

Next expected readout: June 2027 · NCT06690827 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Acute Myeloid Leukemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAllo-RevCAR01-TCD123 targeted CAR-NK cells
OS, median—Not reported—Not reported
Complete remission—Not reported—Not reported
Event-free survival, median—Not reported—Not reported
Duration of response, median—Not reported—Not reported

OS, median

Allo-RevCAR01-T
—Not reported
CD123 targeted CAR-NK cells
—Not reported

Complete remission

Allo-RevCAR01-T
—Not reported
CD123 targeted CAR-NK cells
—Not reported

Event-free survival, median

Allo-RevCAR01-T
—Not reported
CD123 targeted CAR-NK cells
—Not reported

Duration of response, median

Allo-RevCAR01-T
—Not reported
CD123 targeted CAR-NK cells
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Allo-RevCAR01-T: no structured comparison results are available for Acute Myeloid Leukemia.

CD123 targeted CAR-NK cells: no structured comparison results are available for Acute Myeloid Leukemia.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Allo-RevCAR01-T's landscape · CD123 targeted CAR-NK cells's landscape